ReviewEmergent materials2021
Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19).
Review in Emergent materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Editorial: Biomaterials and biologicals for disease treatment.Frontiers in bioengineering and biotechnology · 2025Article
- Research Progress on the Application of Natural Medicines in Biomaterial Coatings.Materials (Basel, Switzerland) · 2024Review
- T Cell and Natural Killer Cell Membrane-Camouflaged Nanoparticles for Cancer and Viral Therapies.ACS applied bio materials · 2024Review
- Biomedical equipments, vaccine and drug in the prevention, diagnosis and treatment of COVID-19.Heliyon · 2023Review
- Biomimetic cell membrane-coated poly(lactic-Bioengineering & translational medicine · 2023Review
- Engineering organ-on-a-chip systems to model viral infections.Biofabrication · 2023Review
- Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics.Frontiers in immunology · 2023Review
- From Biomedical Applications of Alginate towards CVD Implications Linked to COVID-19.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants.Theranostics · 2022Review
- USE OF ARTIFICIAL CELLS AS DRUG CARRIERS.Materials chemistry frontiers · 2021Article
- Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives.International journal of nanomedicine · 2021Review
- Impact of COVID-19 on materials science research innovation and related pandemic response.MRS bulletin · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently emerged novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting corona virus disease 2019 (COVID-19) led to urgent search for methods to prevent and treat COVID-19. Among important disciplines that were mobilized is the biomaterials science and engineering. Biomaterials offer a range of possibilities to develop disease models, protective, diagnostic, therapeutic, monitoring measures, and vaccines. Among the most important contributions made so far from this field are tissue engineering, organoids, and organ-on-a-chip systems, which have been the important frontiers in developing tissue models for viral infection studies. Also, due to low bioavailability and limited circulation time of conventional antiviral drugs, controlled and targeted drug delivery could be applied alternatively. Fortunately, at the time of writing this paper, we have two successful vaccines and new at-home detection platforms. In this paper, we aim to review recent advances of biomaterial-based platforms for protection, diagnosis, vaccination, therapeutics, and monitoring of SARS-CoV-2 and discuss challenges and possible future research directions in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.